Login / Signup

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.

Letizia PolitoJinjoo ShimSara Alsterlind HurvitzChau T DangAdam KnottYolande du ToitEleonora RestucciaThibaut SanglierSandra M Swain
Published in: JCO oncology practice (2023)
There was no statistically significant difference in real-world outcomes between patients treated with paclitaxel/nab-paclitaxel and those treated with docetaxel. Selecting patients using key CLEOPATRA eligibility criteria resulted in rwPFS and rwOS similar to those observed in CLEOPATRA, highlighting the importance of ensuring similar patient populations when comparing clinical trial and real-world data.
Keyphrases